https://www.selleckchem.com/ALK.html
inicians, researchers, and health care decision-makers to explore potential modifications in recommendations and practice guidelines. © AlphaMed Press 2019.LESSONS LEARNED The biweekly GEM plus CBDCA dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. The biweekly GEM plus CBDCA regimen could be considered an alternative to the 3-week regimen in NSCLC. BACKGROUND The gemcitabine (GEM)-carboplatin (CBDCA) combination is widely used for non-small cell lung cancer (NSCLC) and has some efficacy in
Curtir
Comentario
Compartilhar
